Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20041699 | 0.82 | STAT5B (0.70) | STAT5BALDH1A1TP53MAPTL3MBTL1 | |
| SCHEMBL22096015 | 0.67 | STAT5B (1.00) | STAT5BALDH1A1TP53MAPTL3MBTL1 | |
| SCHEMBL9972655 | 0.67 | ALDH1A1 (0.52) | ALDH1A1TP53MAPTL3MBTL1LMNA | |
| SCHEMBL315947 | 0.67 | ALDH1A1 (0.52) | STAT5BALDH1A1TP53MAPTL3MBTL1 | |
| SCHEMBL316289 | 0.64 | ALDH1A1 (0.49) | ALDH1A1TP53MAPTL3MBTL1PKM | |
| SCHEMBL29754948 | 0.64 | TP53 (0.54) | ALDH1A1TP53MAPTL3MBTL1LMNA | |
| SCHEMBL10633527 | 0.62 | HSD17B10 (0.61) | ALDH1A1L3MBTL1GAAPKMHSD17B10 | |
| SCHEMBL29755000 | 0.62 | GAA (0.55) | ALDH1A1TP53MAPTL3MBTL1LMNA | |
| SCHEMBL6629991 | 0.62 | ALDH1A1 (0.44) | STAT5BALDH1A1TP53MAPTL3MBTL1 | |
| SCHEMBL18654133 | 0.62 | HSD17B10 (0.41) | STAT5BALDH1A1TP53MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FREIE UNIVERSITAET BERLIN (DE) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FLT3, MCL1, MYD88 | STAT5B 59/4885ALDH1A1 92/4885TP53 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.